Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2026)

Intellia Therapeutics (NTLA) has 7 years of Long-Term Investments data on file, last reported at $141.3 million in Q1 2026.

• Quarterly Long-Term Investments rose 528.36% year-over-year to $141.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141.3 million (up 528.36% YoY) and the FY2025 annual result came in at $155.2 million, up 250.74% from the prior year.
• Long-Term Investments retreated to $141.3 million in Q1 2026 per NTLA's latest filing, from $155.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $225.0 million in Q1 2023 and bottomed at $7.0 million in Q3 2025.
• The 5-year median for Long-Term Investments is $46.8 million (2024), against an average of $76.2 million.
• The widest annual swing landed in 2022, when Long-Term Investments plunged 89.45%; it then jumped 528.36% in 2026.
• Tracing NTLA's Long-Term Investments over 5 years: stood at $69.3 million in 2022, then surged by 44.02% to $99.9 million in 2023, then slumped by 55.68% to $44.3 million in 2024, then jumped by 250.74% to $155.2 million in 2025, then slipped by 9.01% to $141.3 million in 2026.
• Per Business Quant, the three latest NTLA Long-Term Investments figures stand at $141.3 million (Q1 2026), $155.2 million (Q4 2025), and $7.0 million (Q3 2025).

Peer Comparison